| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | -0.011 | 0.9 |